Normodyne — Competitive Intelligence Brief

Normodyne (LABETALOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta-Adrenergic Blocker. Area: Cardiovascular.

marketed beta-Adrenergic Blocker Beta-1 adrenergic receptor Cardiovascular Small molecule

Target snapshot

Normodyne (LABETALOL) — Merck & Co..

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Normodyne TARGET	LABETALOL	Merck & Co.	marketed	beta-Adrenergic Blocker	Beta-1 adrenergic receptor	1984-01-01
Onoact	LANDIOLOL	Aop Hlth Us	marketed	landiolol	Beta-1 adrenergic receptor	2024-01-01
Betaxon	LEVOBETAXOLOL	Alcon Pharms Ltd	marketed	levobetaxolol	Beta-1 adrenergic receptor	2000-01-01
Genesa	ARBUTAMINE		marketed	arbutamine	Beta-1 adrenergic receptor	1997-01-01
Zebeta	BISOPROLOL	Teva	marketed	beta-Adrenergic Blocker	Beta-1 adrenergic receptor	1992-01-01
Levadil	DILEVALOL		marketed	dilevalol	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Beta-1 adrenergic receptor	1990-01-01
Optipranolol	METIPRANOLOL	Bausch Health	marketed	beta-Adrenergic Blocker	Beta-1 adrenergic receptor	1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (beta-Adrenergic Blocker class)

1. · 1 drug in this class
2. AbbVie · 1 drug in this class
3. Bausch Health · 1 drug in this class
4. Merck & Co. · 1 drug in this class
5. Novartis · 1 drug in this class
6. Pfizer · 1 drug in this class
7. Promius Pharma · 1 drug in this class
8. Teva · 1 drug in this class